VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Weight Loss

Interventions

DRUG: Placebo
DRUG: VK2735

Sponsor

Viking Therapeutics, Inc.